Certara, Inc. (NASDAQ:CERT) Stock Has Average Price Target of $9.92

Shares of Certara, Inc. (NASDAQ:CERT – Get Free Report) have been assigned a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.92.

CERT has been the topic of a number of recent research reports. Weiss Ratings raised shares of Certara from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, November 9th. TD Cowen lifted their target price on Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. KeyCorp upped their target price on Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Jefferies Financial Group restated a “hold” rating and set a $12.00 price objective on shares of Certara in a research note on Friday, November 6th. Finally, Barclays boosted their price target on shares of Certara from $9.00 to $12.00 and gave the company an “equal weight” rating in a report on Friday, November 6th.

Check Out Our Latest Stock Report on CERT

Certara Stock Down 2.9%

Shares of NASDAQ:CERT opened at $11.06 on Friday. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -26.33 and a beta of 1.30. Certara has a 1-year low of $4.45 and a 1-year high of $12.61. The company’s fifty day moving average is $9.83 and its two-hundred day moving average is $7.42. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.58 and a current ratio of 2.58.

Certara (NASDAQ:CERT – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. Certara had a negative net margin of 16.14% and a positive return on equity of 3.36%. The business had revenue of $94.90 million during the quarter, compared to analyst estimates of $92.01 million. During the same period in the previous year, the business posted $0.14 EPS. The company’s quarterly revenue was down 9.3% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. Equities analysts anticipate that Certara will post 0.21 EPS for the current year.

Institutional Trading of Certara

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Certara in the 2nd quarter worth about $123,259,000. Dimensional Fund Advisors LP raised its stake in shares of Certara by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after purchasing an additional 175,024 shares in the last quarter. Haveli Investment Management LLC bought a new stake in shares of Certara during the second quarter valued at about $48,470,000. Jefferies Financial Group Inc. bought a new stake in shares of Certara during the second quarter valued at about $46,446,000. Finally, Royce & Associates LP lifted its holdings in Certara by 6.6% in the third quarter. Royce & Associates LP now owns 2,937,683 shares of the company’s stock worth $27,027,000 after purchasing an additional 181,657 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

(Get Free Report)

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.

See Also

Analyst Recommendations for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.